Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial
| Autor: | Valerio Zoli, Antonello Pinto, Emilio Iannitto, Luigi Rigacci, Alessandra Tucci, Vincenzo Secondo, Annunziata Manna, Stefano Pileri, Atto Billio, Pierfederico Torchio, Francesco Zaja, Alessandro Levis, Andrea Gallamini, Caterina Patti, Corrado Tarella, Maria Rosaria Specchia |
|---|---|
| Přispěvatelé: | Gallamini A., Zaja F., Patti C., Billio A., Specchia MR., Tucci A., Levis A., Manna A., Secondo V., Rigacci L., Pinto A., Iannitto E., Zoli V., Torchio P., Pileri S., Tarella C., Gallamini, A, Zaja, Francesco, Patti, C, Billio, A, Specchia, Mr, Tucci, A, Levis, A, Manna, A, Secondo, V, Rigacci, L, Pinto, A, Iannitto, E, Zoli, V, Torchio, P, Pileri, S, Tarella, C. |
| Jazyk: | angličtina |
| Rok vydání: | 2007 |
| Předmět: |
Adult
medicine.medical_specialty Vincristine Antibodies Neoplasm Immunology Kaplan-Meier Estimate CHOP Antibodies Monoclonal Humanized Biochemistry Gastroenterology Chemoimmunotherapy Antigens CD Antigens Neoplasm Multicenter trial Internal medicine Antineoplastic Combined Chemotherapy Protocols Medicine Humans Multicenter Studies as Topic Alemtuzumab Cyclophosphamide Societies Medical Aged Glycoproteins Dose-Response Relationship Drug business.industry Pralatrexate Antibodies Monoclonal Lymphoma T-Cell Peripheral Cell Biology Hematology Middle Aged medicine.disease Surgery Regimen CD52 Antigen Italy Doxorubicin Prednisone business Progressive disease medicine.drug |
| Popis: | To evaluate in a prospective multicenter trial the feasibility and clinical efficacy of the combination of alemtuzumab (Campath-1H) with the cyclophosphamide/doxorubicin/vincristine/prednisone (CHOP) regimen (CHOP-C) as the primary treatment for patients with peripheral T-cell lymphoma (PTCL), between January 2003 and December 2005, 24 consecutive patients with PTCL entered the study and received 8 CHOP courses. Alemtuzumab was added at 30 mg subcutaneously at day −1 initially to the first 4 courses (4 patients), and then to all 8 courses (20 patients). Complete remission (CR) was achieved in 17 (71%) patients, 1 had partial remission, and 6 had stable/progressive disease. At a median follow-up of 16 months (range, 5-42 months), 14 patients were alive, 9 had died from progressive disease, and 1 had died from pneumonia at day +198 while in CR. So far, 13 are disease-free, with an overall median duration of response of 11 months. The most frequent side effects were grade 4 neutropenia and cytomegalovirus (CMV) reactivation. Major infections were Jacob-Creutzfeldt (J-C) virus reactivation, pulmonary invasive aspergillosis, Staphylococcus sepsis, and pneumonia. This study shows that CHOP-C: (1) is a feasible chemoimmunotherapy regimen; (2) is effective in PTCL with a high rate of CR achievement; and (3) is associated with mostly manageable infectious complications. This clinical trial was registered with the Osservatorio Nazionale sulla Sperimentazione cinica as ID no. 141202. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|